Gain Therapeutics (GANX) Intangibles (2021 - 2026)
Gain Therapeutics (GANX) posted quarterly Intangibles of $90045.0 for Q1 2026, down 28.7% year-over-year from $126291.0 in Q1 2025, and down 12.44% quarter-over-quarter from $102837.0 in Q4 2025.
Gain Therapeutics (GANX) Intangibles (2021 - 2026) Analysis & Trends
Gain Therapeutics' Intangibles history runs 6 years deep, the most recent figure standing at $90045.0 for Q1 2026.
- In Q1 2026, Intangibles fell 28.7% year-over-year to $90045.0; the TTM figure through Mar 2026 stood at $90045.0 (down 28.7% YoY), while the FY2025 annual figure was $102837.0, down 23.41% from the prior year.
- Intangibles for Q1 2026 stood at $90045.0, down from $102837.0 in the prior quarter.
- The five-year high for Intangibles was $213967.0 in Q4 2022, with the low at $90045.0 in Q1 2026.
- The 5-year median for Intangibles is $163500.0 (2024), against an average of $162858.8.
- The sharpest annual moves came in 2022 and 2024: Intangibles advanced 5.61% in 2022, then sank 30.57% in 2024.
- Gain Therapeutics' Intangibles stood at $213967.0 in 2022, then slipped by 9.62% to $193375.0 in 2023, then tumbled by 30.57% to $134268.0 in 2024, then decreased by 23.41% to $102837.0 in 2025, then decreased by 12.44% to $90045.0 in 2026.
- Business Quant data shows GANX's Intangibles at $90045.0 in Q1 2026, $102837.0 in Q4 2025, and $114607.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Gain Therapeutics | 85.97 Mn | 85.97 Mn | - | 76,782.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 76,782.00 |
| Mar 31, 2026 | 90,045.00 |
| Dec 31, 2025 | 102,837.00 |
| Sep 30, 2025 | 114,607.00 |
| Jun 30, 2025 | 127,857.00 |
| Mar 31, 2025 | 126,291.00 |
| Dec 31, 2024 | 134,268.00 |
| Sep 30, 2024 | 156,256.00 |
| Jun 30, 2024 | 158,000.00 |
| Mar 31, 2024 | 169,000.00 |
| Dec 31, 2023 | 193,375.00 |
| Sep 30, 2023 | 189,242.00 |
| Jun 30, 2023 | 205,000.00 |
| Mar 31, 2023 | 209,000.00 |
| Dec 31, 2022 | 213,967.00 |
| Sep 30, 2022 | 208,328.00 |
| Jun 30, 2022 | 207,667.00 |
| Dec 31, 2021 | 202,609.00 |